Letroxyl 2.5 - Kalpa Pharmaceuticals

Before Letrozole, options for estrogen suppression were limited to older drugs with broader hormonal interference and lower efficacy. The introduction of this third-generation aromatase inhibitor in 1997 marked a shift toward more selective, targeted endocrine therapies. Developed by Novartis and marketed as Femara, it quickly earned a place in standard breast cancer treatment. Its off-label use soon followed, particularly in bodybuilding and post-cycle recovery, where strong estrogen control was necessary. Letrozole’s arrival redefined the boundaries of anti-estrogen pharmacology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letroxyl 2.5 by Kalpa Pharmaceuticals, consult with your doctor or healthcare professional.